117th Congress (2021–2023) · Senate bill · Sponsor: Sen. Hassan, Margaret Wood [D-NH]
This page covers S164 in the 117th Congress. Bill numbers start over every Congress, so S164 in another Congress is a different bill.
| Item | Detail |
|---|---|
| Roll-call votes | 1 |
| Chamber | House |
| Latest vote | 2021-04-14: Passed |
| Latest action | 2021-04-23: Became Public Law No: 117-8. |
| Policy area | Health |
| Official record | Congress.gov |
Advancing Education on Biosimilars Act of 2021 This bill requires the Food and Drug Administration (FDA) to advance education and awareness among health care providers about biological products as appropriate, including by developing or improving continuing education programs that address the prescribing of biological products and biosimilars. (A biosimilar is a biological product that is highly similar to an FDA-approved reference biological product and has no clinically meaningful differences from that reference product.) The FDA may also maintain and operate a website to provide educational materials about biological products.
Subjects: Drug safety, medical device, and laboratory regulation, Government information and archives, Health personnel, Licensing and registrations, Medical education, Prescription drugs
Every recorded vote on this bill, newest first, with a link to the official tally. Member-by-member positions are on each member’s profile.
| Date | Chamber | Question | Result | Yea | Nay | Not voting | Record |
|---|---|---|---|---|---|---|---|
| 2021-04-14 | House | 2/3 Yea-And-Nay | Passed | 277 | 6 | 6 | Official tally |
S164 (Advancing Education on Biosimilars Act of 2021) was introduced in the 117th Congress (2021–2023) by Sen. Hassan, Margaret Wood [D-NH].
On 2021-04-23: Became Public Law No: 117-8.
1 recorded vote in the 117th Congress. The most recent, on 2021-04-14, was "2/3 Yea-And-Nay": Passed.